2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1124

The Direct and Indirect Costs of Illness Associated with Systemic Lupus Erythematosus in the USA, UK, France, and Germany: A Structured Review
Abstract Number: 1125

Health Care Resource Utilization and Costs in Patients with Juvenile Idiopathic Arthritis Treated with Abatacept and Other Targeted Disease Modifying Anti-rheumatic Drugs
Abstract Number: 1126

A Medical Assistant Driven Quality Improvement Intervention Increases Rates of DEXA Screening Among RA Patients
Abstract Number: 1127

Interventions to Improve Time to Appointment and Outcome Variables in the Pediatric to Adult Transition of Care in Rheumatology
Abstract Number: 1128

Physician-Patient Interaction and Medication Adherence in Lupus Nephritis
Abstract Number: 1129

Direct Medical and Societal Cost of Opioid Use in Symptomatic Knee Osteoarthritis Patients in the United States
Abstract Number: 1130

The Risk of Toxic Retinopathy Among Patients on Hydroxychloroquine
Abstract Number: 1131

Loss to Follow-up in Registries of Rheumatic Patients Treated with Biologics: A Potentially Valuable Hidden Real-world Data That Is Being Overlooked?
Abstract Number: 1132

Facility-Level Variation in Biologic Disease Modifying Agents for Medicare Enrollees with Rheumatoid Arthritis
Abstract Number: 1133

Medicare Spending (2012-2017) on Disease Modifying Agents Commonly Used in Rheumatoid Arthritis
Abstract Number: 1134

Medicaid Spending (2013-2017) on Disease Modifying Agents Commonly Used in Rheumatoid Arthritis
Abstract Number: 1135

Optimizing the Management of Flares in Patients with Rheumatoid Arthritis with the Help of Non-Physician Providers: Results of a Randomized Controlled Trial
Abstract Number: 1136

Improving Access in an Academic Rheumatology Department by Reducing the No Show Rate
Abstract Number: 1137

Predictors of Health-Related Quality of Life in Patients with Musculoskeletal Diseases: A Longitudinal Analysis from an Electronic Health Record Database
Abstract Number: 1138

Outpatient Costs and Evaluation and Management (E&M) Expenditure Trends in Rheumatoid Arthritis (RA) Patients Treated with Biologic Therapies in US Community Practices

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].